All Products

Featured Products

Newest Products

Research Areas

Plerixafor HCl
new
featured

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202260

CAS#: 155148-31-5 (HCl)

Description: Plerixafor, also known as AMD3100, is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Plerixafor was approved by the U.S. Food and Drug Administration for this indication on December 15, 2008. In Europe, the drug was approved on 29 May 2009.


Price and Availability

Size Price Shipping out time Quantity
50mg USD 150 Same day
100mg USD 250 Same day
200mg USD 450 Same day
500mg USD 850 Same day
1g USD 1250 Same day
2g USD 2150 Same day
5g USD 4250 Same day
10g USD 6950 Same day
Inquire bulk and customized quantity
Pricing updated 2020-08-03. Prices are subject to change without notice.

Plerixafor HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 202260
Name: Plerixafor HCl
CAS#: 155148-31-5 (HCl)
Chemical Formula: C28H62Cl8N8
Exact Mass:
Molecular Weight: 794.46
Elemental Analysis: C, 42.33; H, 7.87; Cl, 35.70; N, 14.10


Related CAS #: 155148-31-5 (HCl)   110078-46-1 (free base)    

Synonym: AMD3100; AMD-3100; AMD 3100; JM 3100; JM3100; JM-3100; SDZ-SID-791; JLK-169; SID-791; JM-2987; Plerixafor HCl; MOZOBIL.

IUPAC/Chemical Name: 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene octahydrochloride

InChi Key: UEUPDYPUTTUXLJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H54N8.8ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H

SMILES Code: [H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.[H]Cl.C1(CN2CCNCCCNCCNCCC2)=CC=C(CN3CCNCCCNCCNCCC3)C=C1


Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#A8T07K17

QC Data:
View QC data: current batch, Lot#A8T07K17

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


Additional Information

Related CAS#
155148-31-5 ( Plerixafor HCl);
110078-46-1 ( Plerixafor Free base)
  


References

1: Fricker SP. Physiology and Pharmacology of Plerixafor. Transfus Med Hemother. 2013 Aug;40(4):237-245. Epub 2013 Jul 19. Review. PubMed PMID: 24179472; PubMed Central PMCID: PMC3776399.

2: Pierelli L, Perseghin P. Plerixafor (Mozobil) and other mobilizing agents. Transfus Apher Sci. 2013 Apr;48(2):133-5. doi: 10.1016/j.transci.2013.02.005. Epub 2013 Apr 9. Review. PubMed PMID: 23582743.

3: Tanhehco YC, Vogl DT, Stadtmauer EA, O'Doherty U. The evolving role of plerixafor in hematopoietic progenitor cell mobilization. Transfusion. 2013 Oct;53(10):2314-26. doi: 10.1111/trf.12102. Epub 2013 Jan 30. Review. PubMed PMID: 23362980.

4: Gardellini A, Babic A, Gigli F, Liptrott SJ, Martinelli G, Laszlo D. Successful mobilisation of peripheral blood stem cells in children using plerixafor: a case report and review of the literature. Blood Transfus. 2013 Apr;11(2):308-10. doi: 10.2450/2012.0052-12. Epub 2012 Oct 10. Review. PubMed PMID: 23114521; PubMed Central PMCID: PMC3626485.

5: Dunn D, Vikas P, Jagasia M, Savani BN. Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant. 2012 Aug;47(8):1136-7. doi: 10.1038/bmt.2011.226. Epub 2011 Nov 14. Review. PubMed PMID: 22080973.

6: Jantunen E, Lemoli RM. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion. 2012 Apr;52(4):906-14. doi: 10.1111/j.1537-2995.2011.03349.x. Epub 2011 Oct 7. Review. PubMed PMID: 21981351.

7: Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review. PubMed PMID: 21861545.

8: Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther. 2011 Sep;11(9):1241-8. doi: 10.1517/14712598.2011.601737. Review. PubMed PMID: 21806478.

9: Mohty M, Duarte RF, Croockewit S, Hübel K, Kvalheim G, Russell N. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia. 2011 Jan;25(1):1-6. doi: 10.1038/leu.2010.224. Review. PubMed PMID: 21224858.

10: Pelus LM, Farag SS. Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma. Stem Cells Cloning. 2011 Feb 27;4:11-22. doi: 10.2147/SCCAA.S6713. Review. PubMed PMID: 24198526; PubMed Central PMCID: PMC3781755.